Genetic Split: Evidence Type 1 Diabetes May Be Two Diseases

Imagine two patients, both diagnosed with type 1 diabetes at age 12, yet their bloodwork and immune profiles tell different stories. One shows signs linked to allergic inflammation. The other bears the fingerprints of a direct cellular assault. Same diagnosis. Different beginnings.

How the study separated the familiar into two paths

A team of researchers in the United States and the United Kingdom applied a genome wide association study to type 1 diabetes in a way that had not been done before. Instead of grouping all cases together, they divided participants by two HLA haplotypes known to carry higher disease risk: HLA-DR3 and HLA-DR4. The sample was large: 9,091 people with type 1 diabetes and 14,157 controls. The results, published in Diabetologia, revealed genomic signals that differed sharply between the two haplotype groups.

GWAS, in brief, scans the genome for variants that occur more often in people with a condition than in those without. But by stratifying patients by HLA background the researchers could see which genes and immune pathways light up in each genetic context. And the patterns were not subtle. The genes implicated in DR3 cases suggested involvement of mast cells, immune cells long associated with allergic responses and inflammation. DR4 cases pointed more clearly to T cells, the adaptive immune soldiers that can directly destroy pancreatic beta cells.

A GWAS (like this for kidney stone disease) associates specific genes with specific diseases. 

Why does that matter? If separate immune circuits lead to the same end point, then type 1 diabetes might better be described as a cluster of related disorders rather than a single uniform disease. Treatment strategies built on the assumption of one mechanism could miss opportunities to intervene earlier or more effectively for particular patient groups.

Implications for treatment, trials, and risk prediction

Personalized medicine becomes more than a buzz phrase here. Consider clinical trials of immunotherapies or preventive interventions: enrolling an undifferentiated population could dilute measurable benefits if some participants have disease driven by mast cell biology while others are T cell dominated. Stratifying trials by HLA-DR3 or HLA-DR4 status could sharpen signals and reveal therapies that work only in one genetic background.

Risk prediction models should follow suit. The study authors argue that DR3 and DR4 status could be integrated into genetic-risk calculators to improve accuracy. Longitudinal studies could then track how autoantibody emergence, environmental exposures, and other factors interact with these haplotypes to influence the timing and course of disease.

There is precedent in medicine for this type of reclassification. The researchers compared the genetic distinctness between DR3-driven and DR4-driven type 1 diabetes to the difference seen between schizophrenia and bipolar disorder. That is not to equate these illnesses clinically, but to emphasize the genetic separateness the study uncovered.

What new therapies might look like

Mast cell modulation is a different therapeutic target than T cell suppression. Drugs or biologics that stabilize mast cells, or blunt their inflammatory mediators, could be explored for patients with a DR3 background. For those with a DR4 profile, the focus may remain on T cell targeted approaches, antigen-specific tolerance strategies, or agents that prevent cytotoxic T cells from attacking beta cells.

That said, many patients will carry combinations of risk factors. The next step is not to oversimplify but to layer information: HLA haplotype, autoantibody profiles, age of onset, and environmental history. Together these data could map the most likely path to disease for any individual.

Expert Insight

Dr. Elena Morales, an immunogeneticist who was not involved in the study, says this kind of stratified analysis is overdue. "We have long known that patients present differently. What this work gives us is a plausible mechanistic basis for that variation. It opens the door to targeted trials and better prediction. The challenge will be translating genetic signals into safe, effective interventions that make a real difference for patients."

The point is pragmatic. Genetic stratification could improve the design of prevention trials and help clinicians pick therapies that align with a patient’s underlying biology. It also raises research questions: how do environmental triggers interact with DR3 versus DR4 backgrounds? Does timing of exposure matter? Which biomarkers best predict progression in each subgroup?

Conclusion

This study reframes type 1 diabetes as potentially heterogeneous at a genetic and mechanistic level. By teasing apart HLA-DR3 and HLA-DR4 backgrounds, researchers have identified distinct immune pathways that may lead to beta cell destruction. The immediate next steps are replication, functional studies to validate the implicated genes and pathways, and designing clinical trials that account for genetic subtypes. For patients and clinicians, the longer-term promise is more precise prevention and treatment that reflect the biology behind an individual’s disease.